All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
BCL-2 is an oncogene that promotes leukemogenesis by blocking programmed cell death. BCL-2 protein activation is downstream of multiple cellular pathways, including the IL-7 receptor, which is described to be mutated in specific ALL subtypes. Therefore, BCL-2 inhibitors like venetoclax are being investigated in ALL.